1-3 of 3
Jingkang Shen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers

Wei Zhou, Peng Fang, Dongan Yu, Hongyuan Ren, Meng You, Long Yin, Fei Mei, Huikai Zhu, Zhenzhen Wang, Hui Xu, Yuxia Cao, Xiaowei Sun, Xiaohong Xu, Jianjun Bi, Jin Wang, Lanping Ma, Xin Wang, Lin Chen, Yongliang Zhang, Xiaowei Cen, Xi Zhu, Liguang Lou, Datao Liu, Xiaoding Tan, Jinliang Yang, Tao Meng, Jingkang Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (8): 913–925.
https://doi.org/10.1158/1535-7163.MCT-22-0743
Published: 01 August 2023
View article titled, Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
Open the PDF for Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers in another window
Includes: Supplementary data
Journal Articles

Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin, Liang Liu, Yun Xing, Tao Meng, Lanping Ma, Jinpeng Pei, Ying Cong, Xuesai Zhang, Zhiqiang Ren, Xin Wang, Jingkang Shen, Ker Yu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (11): 2340–2352.
https://doi.org/10.1158/1535-7163.MCT-20-0076
Published: 03 November 2020
View article titled, Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function
Open the PDF for Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Jing Ai, Yi Chen, Xia Peng, Yinchun Ji, Yong Xi, Yanyan Shen, Xinying Yang, Yi Su, Yiming Sun, Yinglei Gao, Yuchi Ma, Bing Xiong, Jingkang Shen, Jian Ding, Meiyu Geng
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (4): 751–762.
https://doi.org/10.1158/1535-7163.MCT-17-0368
Published: 01 April 2018
View article titled, Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
Open the PDF for Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models in another window
Includes: Supplementary data